Welcome to our dedicated page for GeneDx Holdings SEC filings (Ticker: WGSWW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GeneDx Holdings Corp. filings document the regulatory record for a genomics diagnostics company focused on pediatric and rare disease testing, including whole exome and genome sequencing. Form 8-K reports include quarterly and annual financial results, earnings presentation exhibits, statement presentation changes, non-GAAP measure methodology, and material financing agreements.
The company's disclosures also cover its capital structure, including Class A common stock and Nasdaq-listed warrants under WGSWW. Proxy materials address executive compensation, equity awards, shareholder voting matters, and other governance items, while debt filings describe term-loan arrangements, guarantor subsidiaries, use of proceeds, repayment obligations, and default provisions.
GeneDx Holdings Corp. filed an initial insider ownership report for President Mark A. Gardner on a Form 3. The filing identifies Gardner as an officer of the company but does not list any specific transactions or derivative positions in the data provided.
GeneDx Holdings Corp. filed an initial insider ownership report for President Mark A. Gardner on a Form 3. The filing identifies Gardner as an officer of the company but does not list any specific transactions or derivative positions in the data provided.
GeneDx Holdings Corp. appointed Mark Gardner as President, effective June 15, 2026. He will oversee the company’s lab and commercial operations, report to CEO Katherine Stueland, and join the executive leadership team, while Bryan Dechairo shifts to a role leading product, technology and innovation initiatives.
Gardner previously led molecular genomics and oncology at Quest Diagnostics and held senior roles at Corza Medical, OmniSeq and Thermo Fisher Scientific. His employment agreement includes a $530,000 annual base salary, a target annual bonus equal to 65% of base salary, and $2,000,000 in restricted stock units vesting over four years, along with severance and change‑in‑control protections.
GeneDx Holdings Corp. appointed Mark Gardner as President, effective June 15, 2026. He will oversee the company’s lab and commercial operations, report to CEO Katherine Stueland, and join the executive leadership team, while Bryan Dechairo shifts to a role leading product, technology and innovation initiatives.
Gardner previously led molecular genomics and oncology at Quest Diagnostics and held senior roles at Corza Medical, OmniSeq and Thermo Fisher Scientific. His employment agreement includes a $530,000 annual base salary, a target annual bonus equal to 65% of base salary, and $2,000,000 in restricted stock units vesting over four years, along with severance and change‑in‑control protections.
GeneDx Holdings Corp. chief financial officer Kevin Feeley reported RSU vesting and a related tax sale of common stock. On June 9, 2026, restricted stock units converted into 2,462 shares of Class A Common Stock for no cash consideration. On the same date, he sold 1,266 shares of Class A Common Stock at $53.77 per share in an open-market transaction to cover tax withholding obligations, described as a non-discretionary “sell to cover” event. After these transactions, he beneficially owned 36,486 shares of Class A Common Stock, as well as RSUs representing up to 89,240 additional shares and options to purchase up to 25,906 shares, which vest according to their terms. The RSUs vest in 6.25% quarterly installments, contingent on continued service.
GeneDx Holdings Corp. chief financial officer Kevin Feeley reported RSU vesting and a related tax sale of common stock. On June 9, 2026, restricted stock units converted into 2,462 shares of Class A Common Stock for no cash consideration. On the same date, he sold 1,266 shares of Class A Common Stock at $53.77 per share in an open-market transaction to cover tax withholding obligations, described as a non-discretionary “sell to cover” event. After these transactions, he beneficially owned 36,486 shares of Class A Common Stock, as well as RSUs representing up to 89,240 additional shares and options to purchase up to 25,906 shares, which vest according to their terms. The RSUs vest in 6.25% quarterly installments, contingent on continued service.
GeneDx Holdings CEO Katherine Stueland exercised restricted stock units that converted into 6,546 shares of Class A Common Stock and sold 3,639 shares at about $53.77 per share. The sale was a “sell to cover” transaction to satisfy tax withholding obligations and was not discretionary. After these transactions, she beneficially owned 96,123 shares of common stock, RSUs for up to 324,275 additional shares, and options to purchase up to 107,610 shares that vest over time.
GeneDx Holdings CEO Katherine Stueland exercised restricted stock units that converted into 6,546 shares of Class A Common Stock and sold 3,639 shares at about $53.77 per share. The sale was a “sell to cover” transaction to satisfy tax withholding obligations and was not discretionary. After these transactions, she beneficially owned 96,123 shares of common stock, RSUs for up to 324,275 additional shares, and options to purchase up to 107,610 shares that vest over time.
GeneDx Holdings Corp. reported an insider-related increase in holdings by entities associated with Casdin Capital. Casdin Partners Master Fund, L.P. made open-market purchases of 150,000 Class A common shares at $56.4449 per share on June 4, 2026 and 50,000 shares at $52.8566 per share on June 5, 2026, totaling 200,000 shares. After these trades, the Master Fund held 3,707,164 shares indirectly. Additional positions as of June 4, 2026 included 333,144 shares owned by the Master Fund, 19,247 shares owned by the GP entity, and 20,517 shares owned directly by Eli Casdin, each as separate holdings.
GeneDx Holdings Corp. reported an insider-related increase in holdings by entities associated with Casdin Capital. Casdin Partners Master Fund, L.P. made open-market purchases of 150,000 Class A common shares at $56.4449 per share on June 4, 2026 and 50,000 shares at $52.8566 per share on June 5, 2026, totaling 200,000 shares. After these trades, the Master Fund held 3,707,164 shares indirectly. Additional positions as of June 4, 2026 included 333,144 shares owned by the Master Fund, 19,247 shares owned by the GP entity, and 20,517 shares owned directly by Eli Casdin, each as separate holdings.
GeneDx Holdings Corp. Chief Financial Officer Kevin Feeley reported routine equity compensation activity involving restricted stock units (RSUs) and a tax-related share sale. On June 1, 2026, 717 RSUs converted into the same number of Class A Common shares for no cash cost, reflecting vesting of previously granted awards.
On the same date, Feeley sold 369 shares of Class A Common Stock at $51.74 per share in an open-market transaction solely to cover tax withholding obligations from the RSU vesting, described as a “sell to cover” and not a discretionary trade. After these transactions, he beneficially owned 35,290 shares of Class A Common Stock, plus RSUs representing up to 91,702 additional shares and options to purchase up to 25,906 shares, all subject to their vesting schedules.
GeneDx Holdings Corp. Chief Financial Officer Kevin Feeley reported routine equity compensation activity involving restricted stock units (RSUs) and a tax-related share sale. On June 1, 2026, 717 RSUs converted into the same number of Class A Common shares for no cash cost, reflecting vesting of previously granted awards.
On the same date, Feeley sold 369 shares of Class A Common Stock at $51.74 per share in an open-market transaction solely to cover tax withholding obligations from the RSU vesting, described as a “sell to cover” and not a discretionary trade. After these transactions, he beneficially owned 35,290 shares of Class A Common Stock, plus RSUs representing up to 91,702 additional shares and options to purchase up to 25,906 shares, all subject to their vesting schedules.
GeneDx Holdings Corp. received an updated Schedule 13D/A from investment groups associated with Eli Casdin and Keith Meister, detailing their ownership of the company’s Class A common stock. Based on 29,688,027 shares outstanding as of May 1, 2026, Eli Casdin reports beneficial ownership of 13.7% and Keith Meister reports 17.9%, including shares held through various funds, LLCs, warrants, options and restricted stock units. Corvex Management and Casdin Capital entities are also listed with double‑digit percentage stakes, reflecting significant institutional involvement in GeneDx.
GeneDx Holdings Corp. received an updated Schedule 13D/A from investment groups associated with Eli Casdin and Keith Meister, detailing their ownership of the company’s Class A common stock. Based on 29,688,027 shares outstanding as of May 1, 2026, Eli Casdin reports beneficial ownership of 13.7% and Keith Meister reports 17.9%, including shares held through various funds, LLCs, warrants, options and restricted stock units. Corvex Management and Casdin Capital entities are also listed with double‑digit percentage stakes, reflecting significant institutional involvement in GeneDx.
GeneDx Holdings Corp. reported substantial insider-related buying of its Class A Common Stock by investment funds advised by Corvex Management LP. These funds purchased a total of 351,273 shares in open-market transactions between May 13 and May 15 at weighted average prices within ranges from about $37.78 to $40.60 per share.
After these transactions, the Corvex-advised funds directly hold 4,784,570 shares. In addition, CMLS Holdings LLC holds 333,144 shares, over which Keith A. Meister shares voting and investment discretion, and Meister separately holds 20,129 shares issued upon vesting of restricted stock units for his board service.
GeneDx Holdings Corp. reported substantial insider-related buying of its Class A Common Stock by investment funds advised by Corvex Management LP. These funds purchased a total of 351,273 shares in open-market transactions between May 13 and May 15 at weighted average prices within ranges from about $37.78 to $40.60 per share.
After these transactions, the Corvex-advised funds directly hold 4,784,570 shares. In addition, CMLS Holdings LLC holds 333,144 shares, over which Keith A. Meister shares voting and investment discretion, and Meister separately holds 20,129 shares issued upon vesting of restricted stock units for his board service.
GeneDx Holdings Corp. insiders Eli Casdin and Keith Meister report updated ownership positions in this Schedule 13D amendment. Based on 29,688,027 Shares outstanding as of May 1, 2026, Eli Casdin beneficially owns 3,599,671 Shares, representing 12% of the Class A common stock. Keith Meister beneficially owns 5,356,767 Shares, representing 17.9% of the class. These stakes include Shares held through entities such as CMLS Holdings LLC, Casdin Partners Master Fund, LP and investment funds advised by Corvex Management LP. Certain holdings include 204,141 private placement warrants exercisable at $379.50 per Share, fully vested options and restricted stock units granted for board service. The filing notes that recent trades by the reporting persons were executed as open market transactions.
GeneDx Holdings Corp. insiders Eli Casdin and Keith Meister report updated ownership positions in this Schedule 13D amendment. Based on 29,688,027 Shares outstanding as of May 1, 2026, Eli Casdin beneficially owns 3,599,671 Shares, representing 12% of the Class A common stock. Keith Meister beneficially owns 5,356,767 Shares, representing 17.9% of the class. These stakes include Shares held through entities such as CMLS Holdings LLC, Casdin Partners Master Fund, LP and investment funds advised by Corvex Management LP. Certain holdings include 204,141 private placement warrants exercisable at $379.50 per Share, fully vested options and restricted stock units granted for board service. The filing notes that recent trades by the reporting persons were executed as open market transactions.
GeneDx Holdings Corp. reported significant insider buying linked to director and ten percent owner Keith A. Meister. Investment funds advised by Corvex Management LP made open-market purchases totaling 1,205,147 shares of Class A Common Stock between May 7 and May 11, 2026, at weighted average prices generally in the mid-$30s to low-$40s per share. After these trades, the Corvex-advised funds directly held 4,433,297 shares of Class A Common Stock. The filing states Mr. Meister may be deemed to indirectly beneficially own these shares through his control of Corvex’s general partner, while both Corvex and Mr. Meister disclaim beneficial ownership beyond their pecuniary interest. The filing also notes 333,144 shares held of record by CMLS Holdings LLC, where Mr. Meister shares voting and investment discretion, and 20,129 shares issued to Mr. Meister upon vesting of restricted stock units for his board service.
GeneDx Holdings Corp. reported significant insider buying linked to director and ten percent owner Keith A. Meister. Investment funds advised by Corvex Management LP made open-market purchases totaling 1,205,147 shares of Class A Common Stock between May 7 and May 11, 2026, at weighted average prices generally in the mid-$30s to low-$40s per share. After these trades, the Corvex-advised funds directly held 4,433,297 shares of Class A Common Stock. The filing states Mr. Meister may be deemed to indirectly beneficially own these shares through his control of Corvex’s general partner, while both Corvex and Mr. Meister disclaim beneficial ownership beyond their pecuniary interest. The filing also notes 333,144 shares held of record by CMLS Holdings LLC, where Mr. Meister shares voting and investment discretion, and 20,129 shares issued to Mr. Meister upon vesting of restricted stock units for his board service.